Dr. Ryan A. Lamarca, M.D.
Nephrology (Kidney) (Nephrology Physician)
- Medicare participating
At a glance
- Medical school
- Florida Atlantic University, College of Medicine (2018)
- Years since graduation
- 8
- In the NPI registry since
- 2018
- Medicare patients seen, 2024
- 32
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2018Medical school: Florida Atlantic University, College of Medicine
- 2018Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Nephrology Physician primary
FL license ME146319
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Holy Cross Hospital Ft Lauderdale, FL
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 32
- Services billed
- 134
- Patients’ average age
- 77
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Amlodipine Besylate Other prescribers in Fort Lauderdale, FL | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 2 payments worth $220 in total to this clinician.
| Boehringer Ingelheim Pharmaceuticals, Inc. | $125 |
|---|---|
| Calliditas Therapeutics US Inc. | $95.25 |
| Food and Beverage | $220 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $342,869 in research payments for these studies, mostly to the institutions running them.
- Sherlock Biosciences, Inc. The PROMISE Study
Orasure Technologies Inc. - A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
Eli Lilly and Company · Completed · NCT05929079
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.